@article{f9508a0131364d49b297f230bb2aed7f,
title = "T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines",
abstract = "Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract. Because extranodal NK/T-cell lymphomas (ENKL) are rare malignancies, randomized trials comparing different regimens have not been conducted to date and standard therapy has not yet been established for these patients. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with ENKL as outlined in the NCCN Guidelines for T-Cell Lymphomas.",
author = "Horwitz, {Steven M.} and Ansell, {Stephen M.} and Ai, {Weiyun Z.} and Jeffrey Barnes and Barta, {Stefan K.} and Michael Choi and Clemens, {Mark W.} and Ahmet Dogan and Greer, {John P.} and Ahmad Halwani and Bradley, {M. Haverkos} and Hoppe, {Richard T.} and Eric Jacobsen and Deepa Jagadeesh and Kim, {Youn H.} and Lunning, {Matthew A.} and Amitkumar Mehta and Neha Mehta-Shah and Yahurio Oki and Olsen, {Elise A.} and Barbara Pro and Rajguru, {Saurabh A.} and Satish Shanbhag and Andrei Shustov and Lubomir Sokol and Pallawi Torka and Ryan Wilcox and Basem William and Jasmine Zain and Dwyer, {Mary A.} and Hema Sundar",
note = "Funding Information: Steven M. Horwitz, MD, Panel Chair, has disclosed that he receives consulting fees from Celgene Corporation; Millenium Pharmaceuticals, Inc./Takeda; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; Infinity Pharmaceutials/Verastem, Inc.; Mundipharma International Ltd; and ADC Therapeutics. He also receives grant/research support from Celgene Corporation; Millenium Pharmaceuticals, Inc./Takeda; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; Forty Seven Inc.; Infinity Pharmaceutials/Verastem, Inc.; ADC Therapeutics; and Aileron Therapeutics, Inc. Stephen M. Ansell, MD, PhD, Panel Vice-Chair, has disclosed that he receives grant/research support from Bristol-Myers Squibb Company, Seattle Genetics, Inc., Affimed, Regeneron Pharmaceuticals, Inc., and Pfizer, Inc. Stefan K. Barta, MD, MRCP, MS, Panel Member, has disclosed that he receives grant/research support from Celgene Corporation; Merck & Co., Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceuticals North America, Inc. He also receives consulting fees and honoraria from and serves as a scientific advisor for Janssen Pharmaceutica Products, LP. Bradley M. Haverkos, MD, MPH, MS, Panel Member, has disclosed that he has no relevant financial relationships. Richard T. Hoppe, MD, Panel Member, has disclosed that he has no relevant financial relationships. Matthew A. Lunning, DO, Panel Member, has received grant/research support from Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Constellation Pharmaceuticals; Janssen Scientific Affairs, LLC; Jazz Pharmaceuticals, Inc.; Juno Therapeutics, Inc.; Pharmacyclics, Inc.; and TG Therapeutics, Inc. He also receives consulting fees from AbbVie Inc.; ADC Therapeutics; AstraZeneca Pharmaceuticals LP/Acerta Pharma; Bayer; Celgene Corporation; Epizyme, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceutica Products, LP/Pharmacyclics, Inc.; Juno Therapeutics, Inc.; Kite Pharma, Inc.; Portola Pharmaceuticals, Inc.; sanofi-aventis/Genzyme Corporation; Seattle Genetics, Inc.; and TG Therapeutics, Inc. Neha Mehta-Shah, MD, Panel Member, has disclosed that she has no relevant financial relationships. Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships. Hema Sundar, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships. Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",
year = "2018",
month = feb,
day = "1",
doi = "10.6004/jnccn.2018.0007",
language = "English (US)",
volume = "16",
pages = "123--135",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",
}